 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...106107108109110111112113114115116...235236» |
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Important distinction: FOLFOXIRI, the 🇺🇸 version (lower 5-FU infusion 2400 mg/m2), not the European version (3200 mg/m2), is not the same as FOLFIRINOX. Essentially modified FOLFIRINOX (no bolus 5-FU; CPT-11 cap of 150 mg/m2). ?gFOLFOXIRI? @gabe_a_brooks @DocCatenacci #GI22 https://t.co/XvorxS20U1 (Twitter) - Jan 22, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Admittedly, I do not see as many CRC patients as I did before but I often use upfront FOLFOXIRI for mCRC and actually also as induction chemo (well, FOLFIRINOX there) for locally advanced rectal cancer. (Twitter) - Jan 22, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Panel moderator Dr. Strickler states in the U.S., oncologists are "Less inclined toward FOLFOXIRI". Interested to see who agrees? #GI22 (Twitter) - Jan 22, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Important to discuss the JCOG 0603 trial of hepatectomy alone vs hepatectomy followed by FOLFOX: 🔑 “DFS did not correlate with OS for liver-only metastatic CRC” source: @JCOG_official #GI22 #crcsm (Twitter) - Jan 22, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Graspa (eryaspase) / ERYtech
Good time to plug @mnoel3232's ongoing phase I FOLFIRINOX/eryaspase study for locally advanced/metastatic PDAC ➡️potential synergy with iri/5-FU put to the test! @ChYin89 @RueschCenter @OncoAlert #GI22 #pancsm @ERYTECH_PHARMA https://t.co/fIal94fUt1 https://t.co/0LVACU2c7X (Twitter) - Jan 21, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Interesting idea raised by Dr. Azad Would you enroll your patients in a neoadjuvant FOLFIRINOX+asparaginase in #pancreaticcancer after seeing results of Trybeca-1 #GI22 (Twitter) - Jan 21, 2022
- || Avastin (bevacizumab) / Roche
Biomarker, Clinical, Journal: Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer. (Pubmed Central) - Jan 21, 2022
Application of FOLFOXai could lead to improvements of treatment outcomes for patients with mCRC and other cancers since patients predicted to have less benefit from oxaliplatin-containing regimens might benefit from alternative regimens.
- || leucovorin calcium / Generic mfg.
Clinical, Journal: Unusual presentation of cornea verticillata with intravitreal methotrexate in a case of primary intraocular lymphoma. (Pubmed Central) - Jan 21, 2022
Intravitreal methotrexate was stopped, and the patient was started on frequent topical lubricants, loteprednol, topical folinic acid and oral folic acid. Complete resolution of corneal toxicity was observed at 3 weeks and the injections were suspended as there was no recurrence at 6 months follow-up.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
@drymtn makes an appearance at #GI22 @FlavioRochaMD describes his trial evaluating FOLFIRINOX and Hepatic Artery Infusion Pump for unresectable cholangio. Great trial design! #Livercancer (Twitter) - Jan 21, 2022
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Long-Term Complete Response by Chemotherapy for Distant Lymph Node Metastases after Curative Surgery for Ascending Colon Cancer-A Case Report (Pubmed Central) - Jan 21, 2022
In addition, the regimen was changed to FOLFIRI plus bevacizumab because side effects such as peripheral neuropathy were worsening. Although chemotherapy was discontinued in November 2016, there has been no recurrence and a long-term complete response has been sustained.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Clinical, Journal: A Case of Surgical Resection of Anaplastic Carcinoma of the Pancreas(Pleomorphic Cell Type)with Poor Response to Neoadjuvant Chemotherapy (Pubmed Central) - Jan 21, 2022
Gemcitabine(GEM)plus nab-paclitaxel(PTX)was started as neoadjuvant chemotherapy(NAC)for resectable pancreatic cancer...Anaplastic carcinoma has a poor response to chemotherapy and may be included with cancers showing treatment resistance to NAC, as seen in our case. It is necessary to pay attention to anaplastic carcinoma during the course of NAC for pancreatic cancer.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: A Case of SM Carcinoma of the Sigmoid Colon with Distant Metastasis in the Early Stage after Endoscopic MucosalResection (Pubmed Central) - Jan 21, 2022
It is necessary to pay attention to anaplastic carcinoma during the course of NAC for pancreatic cancer. We present a case of T1 sigmoid adenocarcinoma which developed distant metastasis 3 months after EMR with literature review.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: A Fatal Case of Meningeal Carcinomatosis in a Rectal Cancer Patient Diagnosed with Pathologic Complete Response after Neoadjuvant Chemoradiotherapy (Pubmed Central) - Jan 21, 2022
After the onset of the primary symptoms of meningeal carcinomatosis, his condition deteriorated rapidly. When we encounter patients with colorectal cancer, especially those with poorly differentiated adenocarcinoma, and a continuously increasing CEA level despite no remarkable findings, we should suspect meningeal carcinomatosis and perform further examinations, including sampling the cerebrospinal fluid.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: A Case of Metastatic Pancreatic Ductal Adenocarcinoma Successfully Treated with Modified FOLFIRINOX and Concurrent Radiotherapy (Pubmed Central) - Jan 21, 2022
The relative dose intensities of oxaliplatin, irinotecan and fluorouracil at 6 months after beginning of treatment were 77.6, 84.0 and 88.3 percent, respectively...For 17 months, opioid was not necessary for the control of abdominal or back pain to the end of third-line treatment. Though safety or clinical benefits of modified FOLFIRINOX plus concurrent radiotherapy for metastatic pancreatic ductal adenocarcinoma have not been reported, in this case, such treatment might contribute to prolong prognosis or prevent developing abdominal or back pain.
- || Vectibix (panitumumab) / Amgen, Takeda
Clinical, Journal: A Case of Curative Resection after Neoadjuvant Chemotherapy for Locally-Advanced Sigmoid Colon Carcinoma with Urinary Bladder Invasion (Pubmed Central) - Jan 21, 2022
Subsequently, the patient received adjuvant chemotherapy with 4 courses of mFOLFOX6, and his condition improved with no incidence of cancer recurrence following 8 months after the operation. Neoadjuvant chemotherapy for locally advanced colon cancer is one of the effective treatments for reliable and safe radical resection.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV) (Pubmed Central) - Jan 21, 2022
Currently, she is still undergoing chemotherapy following 7 years since the first visit. Long-term survival can be expected following surgical treatment during chemotherapy.
- ||||| 5-fluorouracil / Generic mfg., Tyvyt (sintilimab) / Eli Lilly, leucovorin calcium / Generic mfg.
Clinical, P3 data, P3 data: top line: Abs #560: Disappointing phase 3 interim analysis of FOLFIRINOX +/- Sintilimab in #pancreatic #cancer failing to demonstrate benefit for PFS and OS for first 110 pts but improved RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22 @ASCOPost #immunotherapy (Twitter) - Jan 21, 2022
- ||||| Preclinical: Check IN MICE off your #GI22 bingo card (but fascinatingly it’s because “mice can tolerate gemcitabine/Abraxane but not FOLFIRINOX” 👀) #pancsm cc: @matthewherper (Twitter) - Jan 21, 2022
- | Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (clinicaltrials.gov) - Jan 21, 2022
P1, N=44, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Long-term survival can be expected following surgical treatment during chemotherapy. Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: Oct 2022 --> Oct 2024
- ||| lunresertib (RP-6306) / Repare Therap
Enrollment open, Combination therapy, Metastases: MINOTAUR: Study of RP-6306 With FOLFIRI in Advanced Solid Tumors (clinicaltrials.gov) - Jan 20, 2022
P1, N=104, Recruiting, Sponsor: Repare Therapeutics
Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: Oct 2022 --> Oct 2024 Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial, Surgery: NACSOC-02: Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer (clinicaltrials.gov) - Jan 20, 2022
P=N/A, N=20, Recruiting, Sponsor: Beijing Chao Yang Hospital
- | New P3 trial, Metastases: RCNAC: Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer (clinicaltrials.gov) - Jan 20, 2022
P3, N=300, Recruiting, Sponsor: Fudan University
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, P2 data: The schema. This is a single arm Phase II trial. 41 pts (40 adeno) received 3 cycles of FOLFOX followed by standard CROSS CRT and surgery. Adj therapy was dealers choice (opened in ‘17) #GI22 2/ (Twitter) - Jan 20, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
My attempt at a “virtual” #GI22 poster walk from my kitchen in #RochesterNY. Please follow this thread and engage if you’d like Here is my poster for Abstract 327: Induction FOLFOX prior to CROSS and surgery in Localized Esophageal Cancer 1/ (Twitter) - Jan 20, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: DCR of FOLFOX-A is promising. However OS data (albeit low # pts) still under 1yr. Definitely worth exploring in Ph3 with IO agents (Twitter) - Jan 20, 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
P2 data: Was happy to speak to @oncologytube regarding our Phase II study evaluating FOLFOX prior to CROSS in Stage 2/3 esophageal cancer @WilmotCancer (Twitter) - Jan 20, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
#GI22 @ASCO always great participating in the @BigTenCRC @hoosiercancer cooperative group trials. I have to say, these are the most efficient cooperative groups that I’ve had the opportunity to work with. FOLFOX-A regimen👇🏾. (Twitter) - Jan 20, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
🔵FOLFOX-A Dr. Al Benson’s regimen 🔵GAP Dr. @rachnatshroff’s regimen 🔵Modified FOLFIRINOX ~ FOLFOXIRI without the bolus, no more than 150 mg/m2 CPT-11 and 2400 not the 3200 mg/m2 🔵FLOT Triplets are making their way back. #GI22 @ASCO #CRCSM #PANCSM #STCSM #ESOCSM #Chemotherapy (Twitter) - Jan 20, 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical: #GI22 Let me introduce to a new chemotherapy regimen name: FOLFOX-A Doublet➕nab-paclitaxel. Our @BigTenCRC @hoosiercancer #clinicaltrials group study presented today. ⏫⏫ORR 42.9% DCR 80% Another backbone? Different profile/tolerability 🆚 FOLFIRINOX https://t.co/TDUud8p11V (Twitter) - Jan 20, 2022
- ||| #GI22 8⃣/CRC ✅IO💊 ➡️V Morris RAPID Abs 12 ⏩Encor➕cetux➕nivo BRAFV600E CRC 👉ORR 45% 🤔BEACON ORR 26% ➡️HJ Lenz ORAL Abs 8 ⏩FOLFOX/Bev +/- nivo ORAL Abs 8 ⛔️⬆️in PFS/OS ✅Also many antiPD1➕VEGF trials ➡️e.g., A Barzi RAPID Abs 15 ⏩Rego Pembro 👉mOS 11mos 👉ORR of 0% (Twitter) - Jan 20, 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Podcast - Phase II: Induction FOLFOX prior to CROSS Richard Dunne, MD @DrR_DUNNE @UofR @WilmotCancer #ASCOGI22 #GICancer #Cancer Link to Audio: https://t.co/Ks6ZqSU8pA (Twitter) - Jan 20, 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Phase II: Induction FOLFOX prior to CROSS Richard Dunne, MD @DrR_DUNNE @UofR @WilmotCancer #ASCOGI22 #GICancer #Cancer https://t.co/8XX37StjDY (Twitter) - Jan 20, 2022
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Journal: Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching. (Pubmed Central) - Jan 20, 2022
Not yet recruiting --> Recruiting Gemcitabine with nab-paclitaxel had a higher disease control rate and lower rates of severe anorexia and diarrhea in our propensity-matched population.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Neoadjuvant and adjuvant therapy of resectable colon cancer - Current standards and developments (Pubmed Central) - Jan 20, 2022
Specifically, recent data of the IDEA study have opened the arena for shared decision making between physicians and patients allowing to define individual treatment approaches based on common assessment of risks and benefits. After completion of perioperative treatment, structured follow-up is of great importance and should be carried out according to the recommendations of the S3 guideline.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Thank you @MPishvaian for the shoutout. Wish I was at #GI22 in person to present our abstract in person. Promising early results with induction FOLFOX priory to CROSS for GE cancer. @WilmotCancer (Twitter) - Jan 20, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: #GI22 2⃣/ ✅G/E/GEJ ➡️Which leads to @DrR_DUNNE Abs 327 ⏩Induction FOLFOX➡️CROSS CRT for localized esophageal/GEJ pts 👉PR/CR in 30/36 pts, pathCR in 8/36 👉2y RFS = 72%, OS NR ☝️This is definitely a strategy that deserves serious consideration for these patients (Twitter) - Jan 20, 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: BTCRC-GI15-015: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jan 20, 2022
P2, N=39, Active, not recruiting, Sponsor: Al B. Benson, III, MD
After completion of perioperative treatment, structured follow-up is of great importance and should be carried out according to the recommendations of the S3 guideline. Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2021 --> Aug 2022
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial (clinicaltrials.gov) - Jan 19, 2022
P3, N=214, Recruiting, Sponsor: Sun Yat-sen University
- | New P2 trial: mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer (clinicaltrials.gov) - Jan 19, 2022
P2, N=100, Recruiting, Sponsor: First Affiliated Hospital of Wenzhou Medical University
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma. (Pubmed Central) - Jan 19, 2022
Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2021 --> Aug 2022 FOLFIRI showed modest efficacy and feasibility for GI-NEC patients and has thus potential for patients who fail the first-line treatment.
- || methotrexate / Generic mfg.
Clinical, Journal: Immune Reconstitution Inflammatory Syndrome Associated with Pneumocystis Jirovecii Pneumonia and Cytomegalovirus Colitis in a Patient with Rheumatoid Arthritis. (Pubmed Central) - Jan 19, 2022
A 68-year-old woman presenting with rheumatoid arthritis was admitted due to pancytopenia caused by methotrexate...Subsequently, after treatment with leucovorin and trimethoprim-sulfamethoxazole, lung consolidation was found to be aggravated, along with a rapidly increasing leukocyte count...Both conditions were associated with immune reconstitution inflammatory syndrome caused by recovery from leukopenia. The patient was successfully treated with intravenous methylprednisolone pulse therapy and ganciclovir.
- |||| monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial completion, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Jan 19, 2022
P1/2, N=383, Completed, Sponsor: MedImmune LLC
The patient was successfully treated with intravenous methylprednisolone pulse therapy and ganciclovir. Active, not recruiting --> Completed
- || pimurutamab (HLX07) / Fosun Pharma
Trial completion date, Trial primary completion date, Metastases: HLX07Ib/II: The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. (clinicaltrials.gov) - Jan 19, 2022
P1/2, N=90, Active, not recruiting, Sponsor: Shanghai Henlius Biotech
Active, not recruiting --> Completed Trial completion date: Oct 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- ||| Hanbeitai (bevacizumab biosimilar) / Fosun Pharma, Eurofarma
Trial completion date: A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC (clinicaltrials.gov) - Jan 19, 2022
P3, N=677, Active, not recruiting, Sponsor: Shanghai Henlius Biotech
Trial completion date: Oct 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Sep 2022 Trial completion date: Apr 2021 --> Apr 2024
- | oxaliplatin / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin (clinicaltrials.gov) - Jan 19, 2022
P2, N=80, Active, not recruiting, Sponsor: University Hospital, Akershus
Trial completion date: Apr 2021 --> Apr 2024 Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Jun 2025 | Trial primary completion date: Dec 2021 --> Jun 2023
- ||| onvansertib (PCM-075) / Cardiff Oncology
Enrollment change, Combination therapy, Metastases: Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation (clinicaltrials.gov) - Jan 19, 2022
P1b/2, N=100, Recruiting, Sponsor: Cardiff Oncology
Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Jun 2025 | Trial primary completion date: Dec 2021 --> Jun 2023 N=44 --> 100
- ||| Lonsurf (trifluridine/tipiracil) / Otsuka
Trial initiation date: ERASE-CRC: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (clinicaltrials.gov) - Jan 19, 2022
P2, N=300, Not yet recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
N=44 --> 100 Initiation date: Dec 2021 --> May 2022
- || Clinical, P2 data, Journal: PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. (Pubmed Central) - Jan 18, 2022
Second-line chemotherapy (Docetaxel or Irinotecan) improves OS which nonetheless remains poor (around 5 months)...Due to a lack of data on FOLFIRI, Durvalumab and Tremelimumab combination, a 2-step safety run-in phase has been performed before the randomised phase II. The safety run-in phase did not show any safety issue and the randomised phase II starts in September 2020.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Review, Journal: Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review. (Pubmed Central) - Jan 18, 2022
As such, this strategy may have a potential as a global standard for patients with LAGC. Outcome of the ongoing clinical trials is expected to establish the global standard of multidisciplinary treatment strategy in patients with LAGC.
- || Retrospective data, Review, Journal: Evidence-based management of HCC: Systematic review and meta-analysis of randomized controlled trials (2002-2020). (Pubmed Central) - Jan 18, 2022
Among 49 high-quality RCTs conducted in HCC during 2002-2020, nine resulted in positive results. A meta-analysis of systemic therapies suggest that immunotherapies may be less effective in non-viral etiologies.